Upbeat TauRx CEO expects new innovative AD treatments within 15 years

With World Alzheimer’s Day fast approaching, drugmakers and patients around the world are raising awareness of the challenges faced, and the progress made, in combating this most intractable of conditions.

While much of the scientific debate has focused on ways to prevent and treat plaques of amyloid protein shown to develop in the brains of Alzheimer’s patients, a small but committed number of medical researchers believe the answer lies in untangling ‘tau’ proteins, which are also associated with the onset of the condition.

Among their number is TauRx Therapeutics chief executive Professor Claude Wischik, who sees the value of World Alzheimer’s Day in sending “a powerful message to governments, policy makers and healthcare professionals.”